Search

Author/Creator Cosentino, Francesco

11. Adverse Epigenetic Signatures by Histone Methyltransferase Set7 Contribute to Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus. (February 2015)

Authors:
Paneni, Francesco; Costantino, Sarah; Battista, Rodolfo; Castello, Lorenzo; Capretti, Giuliana; Chiandotto, Sergio; Scavone, Giuseppe; Villano, Angelo; Pitocco, Dario; Lanza, Gaetano; Volpe, Massimo; Lüscher, Thomas F.; Cosentino, Francesco
Journal:
Circulation
Issue:
Volume 8:Number 1(2015)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

14. Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis. Issue 1 (13th August 2022)

Authors:
Ferrannini, Giulia; Lund, Lars H; Benson, Lina; Rizzo, Manfredi; Almahmeed, Wael; Rosano, Giuseppe M C; Savarese, Gianluigi; Cosentino, Francesco
Journal:
European heart journal
Issue:
Volume 9:Issue 1(2023)
Page Start:
10
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

16. Cardiac, renal, and metabolic effects of sodium–glucose co‐transporter 2 inhibitors: a position paper from the European Society of Cardiology ad‐hoc task force on sodium–glucose co‐transporter 2 inhibitors. (20th July 2021)

Authors:
Herrington, William G.; Savarese, Gianluigi; Haynes, Richard; Marx, Nikolaus; Mellbin, Linda; Lund, Lars H.; Dendale, Paul; Seferovic, Petar; Rosano, Giuseppe; Staplin, Natalie; Baigent, Colin; Cosentino, Francesco
Journal:
European journal of heart failure
Issue:
Volume 23:Number 8(2021)
Page Start:
1260
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

19. Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin. Issue 3 (26th December 2022)

Authors:
Corbin, Karen D.; Dagogo‐Jack, Samuel; Cannon, Christopher P.; Cherney, David Z.I.; Cosentino, Francesco; Frederich, Robert; Liu, Jie; Pong, Annpey; Lin, Jianxin; Cater, Nilo B.; Pratley, Richard E.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 25:Issue 3(2023)
Page Start:
758
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

20. Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV. Issue 7 (29th March 2022)

Authors:
Dagogo‐Jack, Samuel; Cannon, Christopher P.; Cherney, David Z. I.; Cosentino, Francesco; Liu, Jie; Pong, Annpey; Gantz, Ira; Frederich, Robert; Mancuso, James P.; Pratley, Richard E.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 24:Issue 7(2022)
Page Start:
1245
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗